264 related articles for article (PubMed ID: 24843164)
1. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Ortiz B; Fabius AW; Wu WH; Pedraza A; Brennan CW; Schultz N; Pitter KL; Bromberg JF; Huse JT; Holland EC; Chan TA
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8149-54. PubMed ID: 24843164
[TBL] [Abstract][Full Text] [Related]
2. Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis.
Ortiz B; White JR; Wu WH; Chan TA
Oncotarget; 2014 Aug; 5(16):6976-82. PubMed ID: 25138050
[TBL] [Abstract][Full Text] [Related]
3. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Veeriah S; Brennan C; Meng S; Singh B; Fagin JA; Solit DB; Paty PB; Rohle D; Vivanco I; Chmielecki J; Pao W; Ladanyi M; Gerald WL; Liau L; Cloughesy TC; Mischel PS; Sander C; Taylor B; Schultz N; Major J; Heguy A; Fang F; Mellinghoff IK; Chan TA
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9435-40. PubMed ID: 19478061
[TBL] [Abstract][Full Text] [Related]
4. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Solomon DA; Kim JS; Cronin JC; Sibenaller Z; Ryken T; Rosenberg SA; Ressom H; Jean W; Bigner D; Yan H; Samuels Y; Waldman T
Cancer Res; 2008 Dec; 68(24):10300-6. PubMed ID: 19074898
[TBL] [Abstract][Full Text] [Related]
5. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
6. Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways.
Wu L; Gao L; Kong D; Xue H
Dig Dis Sci; 2019 Nov; 64(11):3164-3172. PubMed ID: 31041642
[TBL] [Abstract][Full Text] [Related]
7. Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Peyser ND; Du Y; Li H; Lui V; Xiao X; Chan TA; Grandis JR
PLoS One; 2015; 10(8):e0135750. PubMed ID: 26267899
[TBL] [Abstract][Full Text] [Related]
8. HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss.
Shin CH; Robinson JP; Sonnen JA; Welker AE; Yu DX; VanBrocklin MW; Holmen SL
Oncogene; 2017 Aug; 36(32):4610-4618. PubMed ID: 28368403
[TBL] [Abstract][Full Text] [Related]
9. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
Charest A; Wilker EW; McLaughlin ME; Lane K; Gowda R; Coven S; McMahon K; Kovach S; Feng Y; Yaffe MB; Jacks T; Housman D
Cancer Res; 2006 Aug; 66(15):7473-81. PubMed ID: 16885344
[TBL] [Abstract][Full Text] [Related]
10. IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Zhang F; Wang B; Qin T; Wang L; Zhang Q; Lu Y; Song B; Yu X; Li L
Mol Cell Biochem; 2020 Oct; 473(1-2):1-13. PubMed ID: 32602014
[TBL] [Abstract][Full Text] [Related]
11. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
Van Renne N; Roca Suarez AA; Duong FHT; Gondeau C; Calabrese D; Fontaine N; Ababsa A; Bandiera S; Croonenborghs T; Pochet N; De Blasi V; Pessaux P; Piardi T; Sommacale D; Ono A; Chayama K; Fujita M; Nakagawa H; Hoshida Y; Zeisel MB; Heim MH; Baumert TF; Lupberger J
Gut; 2018 May; 67(5):953-962. PubMed ID: 28159835
[TBL] [Abstract][Full Text] [Related]
12. A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma.
Rahme GJ; Luikart BW; Cheng C; Israel MA
Neuro Oncol; 2018 Feb; 20(3):332-342. PubMed ID: 29016807
[TBL] [Abstract][Full Text] [Related]
13. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.
Kohno T; Otsuka A; Girard L; Sato M; Iwakawa R; Ogiwara H; Sanchez-Cespedes M; Minna JD; Yokota J
Genes Chromosomes Cancer; 2010 Apr; 49(4):342-52. PubMed ID: 20073072
[TBL] [Abstract][Full Text] [Related]
14. High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma.
Giefing M; Zemke N; Brauze D; Kostrzewska-Poczekaj M; Luczak M; Szaumkessel M; Pelinska K; Kiwerska K; Tönnies H; Grenman R; Figlerowicz M; Siebert R; Szyfter K; Jarmuz M
Genes Chromosomes Cancer; 2011 Mar; 50(3):154-66. PubMed ID: 21213369
[TBL] [Abstract][Full Text] [Related]
15. PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin.
Bae WJ; Ahn JM; Byeon HE; Kim S; Lee D
J Exp Clin Cancer Res; 2019 Dec; 38(1):484. PubMed ID: 31805999
[TBL] [Abstract][Full Text] [Related]
16. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.
Jiang Y; Janku F; Subbiah V; Angelo LS; Naing A; Anderson PM; Herzog CE; Fu S; Benjamin RS; Kurzrock R
Oncotarget; 2013 Jun; 4(6):884-9. PubMed ID: 23800680
[TBL] [Abstract][Full Text] [Related]
17. MiR-324-5p/PTPRD/CEBPD axis promotes papillary thyroid carcinoma progression via microenvironment alteration.
Yang Y; Xia S; Zhang L; Wang W; Chen L; Zhan W
Cancer Biol Ther; 2020 Jun; 21(6):522-532. PubMed ID: 32151175
[TBL] [Abstract][Full Text] [Related]
18. Inositol Polyphosphate-5-Phosphatase F (INPP5F) inhibits STAT3 activity and suppresses gliomas tumorigenicity.
Kim HS; Li A; Ahn S; Song H; Zhang W
Sci Rep; 2014 Dec; 4():7330. PubMed ID: 25476455
[TBL] [Abstract][Full Text] [Related]
19. Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.
Vanbrocklin MW; Robinson JP; Lastwika KJ; McKinney AJ; Gach HM; Holmen SL
Neuro Oncol; 2012 Jan; 14(1):34-42. PubMed ID: 22015595
[TBL] [Abstract][Full Text] [Related]
20. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
